Fulcrum Therapeutics (FULC) Asset Utilization Ratio (2020 - 2025)
Fulcrum Therapeutics (FULC) posted quarterly Asset Utilization Ratio of 0.34 for Q2 2025, up 9.51% year-over-year from 0.31 in Q2 2024, and up 14.47% quarter-over-quarter from 0.3 in Q4 2024.
Fulcrum Therapeutics (FULC) Asset Utilization Ratio (2020 - 2025) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Asset Utilization Ratio for 6 consecutive years, with 0.34 the latest figure, recorded in Q2 2025.
- In Q2 2025, Asset Utilization Ratio rose 9.51% year-over-year to 0.34; the TTM figure through Jun 2025 stood at 0.34 (up 9.51% YoY), while the FY2024 annual figure was 0.31, up 2564.82% from the prior year.
- Asset Utilization Ratio grew to 0.34 in Q2 2025 per FULC's latest filing, from 0.3 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.34 in Q2 2025 and bottomed at 0.01 in Q3 2023.
- Historically, Asset Utilization Ratio has averaged 0.11 across 5 years, with a median of 0.07 in 2022.
- Annual changes were most pronounced in 2023 — Asset Utilization Ratio tumbled 85.94% — and 2024, when it surged 3064.27%.
- Fulcrum Therapeutics' Asset Utilization Ratio stood at 0.08 in 2021, then plunged by 65.79% to 0.03 in 2022, then sank by 60.89% to 0.01 in 2023, then jumped by 2735.39% to 0.3 in 2024, then gained by 14.47% to 0.34 in 2025.
- Business Quant data shows FULC's Asset Utilization Ratio at 0.34 in Q2 2025, 0.3 in Q4 2024, and 0.28 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 0.34 |
| Dec 31, 2024 | 0.30 |
| Sep 30, 2024 | 0.28 |
| Jun 30, 2024 | 0.31 |
| Mar 31, 2024 | 0.01 |
| Dec 31, 2023 | 0.01 |
| Sep 30, 2023 | 0.01 |
| Jun 30, 2023 | 0.01 |
| Mar 31, 2023 | 0.01 |
| Dec 31, 2022 | 0.03 |
| Sep 30, 2022 | 0.05 |
| Jun 30, 2022 | 0.07 |
| Mar 31, 2022 | 0.07 |
| Dec 31, 2021 | 0.08 |
| Sep 30, 2021 | 0.09 |
| Jun 30, 2021 | 0.10 |
| Mar 31, 2021 | 0.09 |
| Dec 31, 2020 | 0.06 |